# Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid

> **NCT00437450** · PHASE2 · UNKNOWN · sponsor: **Groupe Francophone des Myelodysplasies** · enrollment: 99 (—)

## Conditions studied

- Anemia in Myelodysplastic Syndromes

## Interventions

- **DRUG:** Epoetin/Atra

## Key facts

- **NCT ID:** NCT00437450
- **Lead sponsor:** Groupe Francophone des Myelodysplasies
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** 2005-09
- **Target enrollment:** 99 (—)
- **Last updated:** 2009-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00437450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00437450, "Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00437450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*